Patient Services

Genzyme has a long history and ongoing commitment to researching and developing treatments for people living with lysosomal storage disorders such as Pompe disease. Our comprehensive offering includes not only enzyme replacement therapies like Lumizyme® (alglucosidase alfa), but also a variety of services and materials to support U.S. patients affected by Pompe disease.

Our goal is to help patients with a medical need for Lumzyme obtain access to treatment. We aim to educate on insurance issues, help identify alternative sources of coverage, and provide assistance with billing and reimbursement. Our experienced Case Managers are healthcare professionals employed by Genzyme and knowledgeable about the intricacies of coverage for Lumizyme, while our Charitable Access Program can help meet the needs of qualified patients facing insurance or financial difficulties.

Care Coordination: Personalized Support for Patients

Whether you've just been diagnosed or have been living with Pompe disease for awhile, managing your access to treatment can be a challenge. Genzyme Care Coordination offers patients personalized support on insurance and other matters at no cost from a dedicated Case Manager, who can provide one-on-one assistance tailored to your unique needs. To contact a Case Manager, call 800-745-4447, option 3.

Find out more about Genzyme Care Coordination

Genzyme offers all services in compliance with patient privacy regulations (HIPAA).

INDICATION

LUMIZYME® (alglucosidase alfa) is an enzyme replacement therapy for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).

IMPORTANT SAFETY INFORMATION

If you or your child is taking Lumizyme, you should know that severe and potentially life-threatening allergic-type reactions known as anaphylaxis or severe hypersensitivity reactions, and other severe reactions related to the immune system may occur during and after Lumizyme treatment. Reactions may include, for example, kidney dysfunction, extreme difficulty breathing, shallow breathing, abnormal heart rate, low blood pressure, or throat tightness (including face, tongue and lip swelling) and skin lesions.

If you or your child has previously experienced these severe reactions, from any cause, you may require close observation during and after Lumizyme administration. You should discuss with your physician the signs and symptoms of anaphylaxis and hypersensitivity reactions. Anaphylaxis or severe hypersensitivity reactions are potentially very dangerous. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide you with immediate medical care. Appropriate medical support measures, including those that may be used to restart the heart or breathing, may be administered when you are being infused with Lumizyme. Should treatment be discontinued, your physician may discuss restarting therapy. You may require close observation during infusions with Lumizyme administration following a severe hypersensitivity reaction.

If you or your child has an illness (i.e. a chronic breathing condition) or has compromised heart function, there may be risk of acute heart and or lung failure, and your doctor may decide that close observation during and after Lumizyme administration may be necessary.

You or your child may be monitored for the development of systemic immune-mediated reactions while receiving Lumizyme. If these reactions occur, your doctor may discontinue the infusion and initiate appropriate medical treatment.

WARNING AND PRECAUTIONS

Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide you with immediate medical care.

Immune-Mediated Reactions: If you or your child has an illness (i.e. a chronic breathing condition) or has compromised heart function, there may be risk of acute heart and or lung failure, and your doctor may decide that close observation during and after Lumizyme administration may be necessary.

Risk of Acute Cardiorespiratory Failure: Infant Pompe patients with heart or breathing problems may be at risk for increasing the seriousness of these problems as a result of Lumizyme administration, and your child’s doctor may require additional monitoring for these infants.

ADVERSE REACTIONS

The most frequently reported adverse reactions during Lumizyme studies in patients were allergy reactions and included: anaphylaxis, rash, fever, flushing/feeling hot, hives, headache, excessive sweating, nausea, cough, less oxygen in the blood, fast heart rate, rapid breathing, chest discomfort, dizziness, muscle twitching, agitation, bluish or purple skin, redness of skin, high blood pressure/increased blood pressure, facial paleness, chills, tremor, vomiting, fatigue, and muscle pain.

SPECIAL POPULATIONS

If you are pregnant, you should use Lumizyme only if your doctor has determined that its use outweighs any risks to your unborn child.

To report suspected adverse reactions, contact Genzyme at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full prescribing information for complete details, including boxed warning.